Pharmaceuticals
TNS Safe Treatment for Ocular Pain
Study suggests three- to six-month use of a trigeminal neurostimulator decreased eye pain, light and wind sensitivity, and burning sensations.
06/01/2021
Stay Alert for Systemic Med Surprises
Many ocular adverse effects may be hiding inside your patient’s pill bottle. Here’s a new way to think about them.
05/15/2021
Managing Miotics and Mydriatics
Take a closer look at old, new and future uses of these drugs.
05/15/2021
Using Antibiotics in Anterior Segment Care
Bacterial ocular and periocular infections are common in adults and children, but choosing an effective treatment strategy relies on more than an accurate clinical diagnosis.
05/15/2021
Dose Escalation
A number of new and exciting pharmaceuticals to help manage ocular disease are on the horizon. Get to know them here.
05/15/2021
2021 ARMOR Results Find Staph Resistance Still Problematic
However, S. aureus had a significant decrease in methicillin resistance.
05/04/2021
Economic Burden Worsens for Glaucoma Patients
Studies found additional IOP-lowering drops led to higher costs with only short-term benefits and observed a spike in brand name med prices.
03/24/2021
Atropine Penetration Minimally Affected by Preservatives
Stability and safety of the drug are better predictors of successful outcomes.
02/16/2021
Mississippi Pushes for Expanded Scope of Practice
Proposal includes oral steroids, lid lesion care and laser capsulotomy privileges.
02/09/2021
Glaucoma Patients More Likely to Respond to Steroids
However, longer axial length and a heavier medication burden may decrease the effectiveness of therapy post-op.
02/09/2021
